Boston Scientific Falls on Sales Hit After August Cyberattack
Boston Scientific Corp. cut its sales forecast, citing a cyberattack in August that disrupted operations. It now expects Q4 sales to decline and full-year adjusted EPS of $3.16-$3.18, below analysts' estimate of $3.23. Shares fell 14% in premarket trading.
How this was made
The 30-second read
Why it matters
The guidance cut and immediate share decline suggest heightened short‑term risk for the stock.
Market read
First‑report of a material guidance downgrade for a large‑cap med‑tech firm, driving a notable pre‑market price drop.
What to watch
Potential insurance recoveries or cost‑saving measures post‑attack could mitigate earnings hit.
Background
Boston Scientific disclosed a cyberattack that disrupted operations and prompted a downgrade of its full‑year sales outlook and earnings guidance.
Ticker impact
Boston Scientific lowered its full-year adjusted EPS to $3.16‑$3.18 and warned Q4 sales will decline, sending the stock down as much as 14% pre‑market.
likely further downside as investors price in weaker outlook
Guidance revisions are material for a large‑cap med‑tech firm and the stock already fell 14% on the news.
Market effects
May weigh on other med‑device peers as investors reassess demand amid cyber‑risk concerns.
Limited to U.S. markets; no broader regional effect noted.
Modest; primarily a company‑specific catalyst.
Counterpoint
If the cyberattack impact is short‑lived, the stock could rebound once operations normalize.
Key entities
- CompanyBoston Scientific Corp.
Medical device maker reporting weaker guidance after a cyberattack.
